Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Therapy for Relapsed/Refractory Hematologic Malignancies
NCT06911710Phase 2Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Nov 2024
- Primary completion
- Feb 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LV20.19 CAR-T in B cell lymphoma, acute myeloid leukemia (AML), multiple myeloma (MM) and 4 more, sponsored by Tianjin Medical University General Hospital. Primary endpoint: Incidence of adverse events at Day 28. Started Nov 2024; status: recruiting.
02
Drugs
LV20.19 CAR-T
03
Conditions
B cell lymphomaacute myeloid leukemia (AML)multiple myeloma (MM)B cell acute lymphoblastic leukemia (B-ALL)t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT06911710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911710.